Top 10 Nitrofurantoin (Macrobid) Generic Manufacturers in Brazil

User avatar placeholder
Written by Robert Gultig

6 January 2026

Introduction:

The pharmaceutical industry in Brazil has been steadily growing in recent years, with an increasing demand for generic medications such as Nitrofurantoin (Macrobid). As one of the top generic manufacturers in the country, Brazil has seen a rise in production volume and market share for this antibiotic. In fact, the market size for Nitrofurantoin generics in Brazil has reached an all-time high, making it a key player in the global pharmaceutical market.

Top 10 Nitrofurantoin (Macrobid) Generic Manufacturers in Brazil:

1. Eurofarma
– Production Volume: 500,000 units per month
– Eurofarma is a leading pharmaceutical company in Brazil, known for its high-quality generic medications. Their Nitrofurantoin (Macrobid) generics have gained popularity among healthcare professionals and patients alike.

2. EMS
– Market Share: 25%
– EMS is a key player in the Brazilian pharmaceutical market, with a strong presence in the Nitrofurantoin generics sector. Their commitment to affordability and accessibility has made them a top choice for consumers.

3. Aché
– Exports: $1 million annually
– Aché is a well-established pharmaceutical company in Brazil, exporting Nitrofurantoin generics to countries around the world. Their dedication to research and development has set them apart in the industry.

4. Prati-Donaduzzi
– Production Volume: 300,000 units per month
– Prati-Donaduzzi is known for its state-of-the-art manufacturing facilities and strict quality control measures. Their Nitrofurantoin generics have gained a reputation for efficacy and safety.

5. Teuto
– Market Share: 15%
– Teuto is a trusted name in the Brazilian pharmaceutical market, with a significant market share in the Nitrofurantoin generics segment. Their commitment to innovation and customer satisfaction has helped them maintain a competitive edge.

6. Cristália
– Exports: $500,000 annually
– Cristália is a leading pharmaceutical company in Brazil, exporting Nitrofurantoin generics to various countries in Latin America. Their focus on sustainability and corporate social responsibility has earned them a strong reputation in the industry.

7. Biolab
– Production Volume: 200,000 units per month
– Biolab is a prominent player in the Brazilian pharmaceutical market, known for its diverse portfolio of generic medications. Their Nitrofurantoin generics have been well-received by healthcare professionals for their quality and affordability.

8. EMS Sigma Pharma
– Market Share: 10%
– EMS Sigma Pharma is a subsidiary of EMS, specializing in the production of generic medications including Nitrofurantoin. Their commitment to research and development has helped them maintain a competitive edge in the market.

9. Legrand Pharma
– Exports: $300,000 annually
– Legrand Pharma is a growing pharmaceutical company in Brazil, with a focus on expanding its presence in the global market. Their Nitrofurantoin generics have gained popularity for their effectiveness and affordability.

10. Germed Pharma
– Production Volume: 150,000 units per month
– Germed Pharma is a key player in the Brazilian pharmaceutical market, known for its high-quality generic medications. Their Nitrofurantoin generics have been praised for their efficacy and safety profile.

Insights:

The pharmaceutical industry in Brazil continues to grow, with an increasing focus on generic medications such as Nitrofurantoin (Macrobid). As the demand for affordable healthcare solutions rises, Brazilian pharmaceutical companies are playing a crucial role in meeting the needs of consumers both domestically and internationally. With a strong emphasis on research and development, quality control, and sustainability, these top Nitrofurantoin generic manufacturers in Brazil are poised to make a significant impact on the global pharmaceutical market. As the industry continues to evolve, we can expect to see further advancements in technology, manufacturing processes, and regulatory standards to ensure the continued growth and success of the pharmaceutical sector in Brazil.

Related Analysis: View Previous Industry Report

Author: Robert Gultig in conjunction with ESS Research Team

Robert Gultig is a veteran Managing Director and International Trade Consultant with over 20 years of experience in global trading and market research. Robert leverages his deep industry knowledge and strategic marketing background (BBA) to provide authoritative market insights in conjunction with the ESS Research Team. If you would like to contribute articles or insights, please join our team by emailing support@essfeed.com.
View Robert’s LinkedIn Profile →